A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes

Part of paid clinical trials in Pelham, Alabama.

Sponsor
Eli Lilly and Company
Study ID
NCT05872620
Phase
PHASE3
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Orforglipron — DRUG
    Administered orally
  • Placebo — DRUG
    Administered orally

Study Details

This study will investigate the safety and efficacy of once daily oral treatment with orforglipron compared with placebo on body weight in adult participants with obesity or overweight and type 2 diabetes. The study will last about 77 weeks and may include up to 22 visits.

Key Dates

Start date
Jun 5, 2023
Status verified
Sep 2025
Primary completion
Aug 8, 2025
Completion
Aug 8, 2025

Study Design

Enrollment
1,613 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Orforglipron Dose 1
    Participants will receive orforglipron administered orally.
  • Experimental: Orforglipron Dose 2
    Participants will receive orforglipron administered orally.
  • Experimental: Orforglipron Dose 3
    Participants will receive orforglipron administered orally.
  • Placebo Comparator: Placebo
    Participants will receive placebo

Primary Outcome Measure

Mean Percent Change from Baseline in Body Weight [ Time Frame: Baseline, Week 72 ]

Locations (37)

FacilityCityStateZIPSite coordinators
Cahaba Research - PelhamPelhamAlabama35124-
Novak Clinical Research - Tucson - North La Cholla BoulevardTucsonArizona85741-
Yuma Clinical TrialsYumaArizona85364-
AMCR InstituteEscondidoCalifornia92025-
Velocity Clinical Research, Huntington ParkHuntington ParkCalifornia90255-
Velocity Clinical Research, WestlakeLos AngelesCalifornia90057-
Catalina Research Institute, LLCMontclairCalifornia91763-
University Clinical Investigators, Inc.TustinCalifornia92780-
Encore Medical ResearchHollywoodFlorida33024-
East Coast Institute for Research, LLCJacksonvilleFlorida32216-
South Florida Clinical Research InstituteMargateFlorida33063-
Suncoast Clinical Research, Inc.New Port RicheyFlorida34652-
Balanced Life Health Care Solutions/SKYCRNGLawrencevilleGeorgia30046-
Endocrine Research Solutions, Inc.RoswellGeorgia30076-
North Georgia Clinical ResearchWoodstockGeorgia30189-
Pacific Diabetes & Endocrine CenterHonoluluHawaii96813-
Solaris Clinical ResearchMeridianIdaho83646-
Iowa Diabetes and Endocrinology Research CenterWest Des MoinesIowa50265-
MedStar Good Samaritan HospitalBaltimoreMaryland21239-
Arcturus Healthcare , PLC, Troy Internal Medicine Research DivisionTroyMichigan48098-
StudyMetrix ResearchCity of Saint PetersMissouri63303-
Las Vegas Medical ResearchLas VegasNevada89128-
IMA Clinical ResearchAlbuquerqueNew Mexico87109-
Albany Medical College, Division of Community EndocrinologyAlbanyNew York12203-
Albany Stratton VA Medical CenterAlbanyNew York12208-
NYC Research INCLong Island CityNew York11106-
Accellacare - RaleighRaleighNorth Carolina27609-
Summit HeadlandsPortlandOregon97210-
Alliance for Multispecialty Research, LLCKnoxvilleTennessee37909-
Velocity Clinical Research, DallasDallasTexas75230-
Soma Clinical TrialsDenisonTexas75020-
Epic Medical Research - DeSotoDeSotoTexas75115-
Biopharma Informatic, LLCHoustonTexas77043-
Diabetes and Glandular Disease CenterSan AntonioTexas78229-
VIP TrialsSan AntonioTexas78230-
Charlottesville Medical ResearchCharlottesvilleVirginia22911-
Universal Research GroupTacomaWashington98405-

Related coverage on Hipa.ai

Find similar trials in Pelham, AL

By condition
Obesity / overweightType 2 diabetes
By specialty
EndocrinologyMetabolic healthWeight loss
By research site
Cahaba Research - Pelham· Pelham, ALNovak Clinical Research - Tucson - North La Cholla Boulevard· Tucson, AZYuma Clinical Trials· Yuma, AZAMCR Institute· Escondido, CAVelocity Clinical Research, Huntington Park· Huntington Park, CAVelocity Clinical Research, Westlake· Los Angeles, CA

Related Studies